The Technical Analyst
Monte Rosa Therapeutics, [GLUE]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Monte Rosa Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-1.18% $5.85
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 293.40 mill |
| EPS: | -2.63 |
| P/E: | -2.22 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 50.15 mill |
| Avg Daily Volume: | 0.135 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.22 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.38x |
| Company: PE -2.22 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.597 (-72.71%) $-4.25 |
| Date: 2024-04-20 |
| Expected Trading Range (DAY) |
|---|
|
$ 5.16 - 6.54 ( +/- 11.85%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-02 | Warmuth Markus | Buy | 346 000 | Stock Option (Right to Buy) |
| 2024-01-02 | Wallace Owen B. | Buy | 119 000 | Stock Option (Right to Buy) |
| 2024-01-02 | Jones Jullian G | Buy | 79 000 | Stock Option (Right to Buy) |
| 2024-01-02 | Janku Filip | Buy | 121 000 | Stock Option (Right to Buy) |
| 2024-01-02 | Nickson Philip | Buy | 109 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 92.69 |
| Last 98 transactions |
| Buy: 57 206 836 | Sell: 164 598 288 |
Forecast:
16:00 - $5.86
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $5.86
Forecast 2: 16:00 - $5.86
Forecast 3: 16:00 - $5.86
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.85 (-1.18% ) |
| Volume | 0.111 mill |
| Avg. Vol. | 0.135 mill |
| % of Avg. Vol | 82.07 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GLUE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:03 | sell | $4.74 | N/A | Active |
|---|
GLUE
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2024-03-14 07:00:00 - Press Release
Monte Rosa Therapeutics Announces Fourth Quarter And Full Year 2023 Financial Results And Provides Corporate Update
Mrt-2359, a molecular glue degrader (mgd) being developed for myc-driven solid tumors, advancing in ongoing phase 1/2 clinical trial; program on track with determination of recommended phase 2 dose expected in q2 2024 mrt-6160, a vav1-directed mgd designed to treat systemic and neurological autoimmune diseases, progressing toward expected ind submission in q2 2024 and initiation of phase 1 sad/mad study midyear mrt-8102 nominated as first development candidate for nek7 program, targeting diseases driven by il-1 b and the nlrp3 inflammasome; ind submission expected in q1 2025 entered into strategic discovery collaboration with roche, further expanding potential applications of queen™ discovery engine strong cash position expected to fund operations into h1 2026 and enable advancement of mrt-2359, mrt-6160, and mrt-8102 programs through clinical milestones boston, march 14, 2024 (globe newswire) -- monte rosa therapeutics, inc...
2024-03-11 07:00:00 - Press Release
Monte Rosa Therapeutics Announces Initiation Of Ind Enabling Studies For Mrt-8102, A First-in-class Nek7 Directed Molecular Glue Degrader And Nlrp3/il-1Β Pathway Inhibitor
Mrt-8102 nominated as first nek7-directed development candidate, targeting inflammatory diseases driven by il-1Β and the nlrp3 inflammasome mrt-8102 and other nek7 program mgds are potentially applicable across a range of inflammatory disorders, metabolic disorders, as well as ocular and neurological diseases ind-enabling studies ongoing; ind submission anticipated in q1 2025 boston, march 11, 2024 (globe newswire) -- monte rosa therapeutics, inc. (nasdaq: glue), a clinical-stage biotechnology company developing novel molecular glue degrader (mgd)-based medicines, today announced a novel development candidate, mrt-8102, a potent, highly selective and orally bioavailable nima related kinase 7 (nek7)-directed mgd...
2024-01-31 07:00:00 - Press Release
Monte Rosa Therapeutics To Participate In Upcoming Investor Conferences
Boston, jan. 31, 2024 (globe newswire) -- monte rosa therapeutics (nasdaq: glue), a clinical-stage biotechnology company developing novel molecular glue degrader (mgd)-based medicines, today announced that management will participate in the following investor conferences: guggenheim 6th annual biotechnology conference (new york, ny) – markus warmuth, m.d., chief executive officer, to participate in fireside chat, february 7, 2024, at 1:30 p.m.
2024-01-08 07:15:00 - Press Release
Monte Rosa Therapeutics Provides Corporate Update And Key Anticipated Milestones For 2024
Phase 1/2 clinical trial of mrt-2359 in myc-driven solid tumors on track; recommended phase 2 dose (rp2d) expected in q2 2024 received us fda fast track designation for mrt-2359 for previously treated, metastatic small cell lung cancer with l- or n-myc expression mrt-6160, a vav1-directed mgd, anticipated to initiate phase 1 study in mid-2024, supporting potential future phase 2 proof-of-concept studies in multiple autoimmune diseases strong cash position expected to fund operations into h1 2026 and enable advancement of pipeline programs through significant early clinical milestones company to present at j.p. morgan healthcare conference on wednesday, january 10, 2024, at 3:00 p.m.
2024-01-03 07:00:00 - Press Release
Monte Rosa Therapeutics To Present At The 42nd Annual J.p. Morgan Healthcare Conference
Boston, mass., jan. 03, 2024 (globe newswire) -- monte rosa therapeutics, inc. (nasdaq: glue), a clinical-stage biotechnology company developing novel molecular glue degrader (mgd)-based medicines, today announced that markus warmuth, m.d.
Latest News
2024-04-10 09:51:07 - Zacks Investment Research
Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why
Monte Rosa Therapeutics (GLUE) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
2024-04-04 10:56:05 - Zacks Investment Research
Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?
The consensus price target hints at a 107.8% upside potential for Monte Rosa Therapeutics (GLUE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-03-22 09:51:07 - Zacks Investment Research
Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why
Monte Rosa Therapeutics (GLUE) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
2024-03-19 10:56:04 - Zacks Investment Research
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to an 117.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2024-01-31 07:00:00 - GlobeNewsWire
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Guggenheim 6th Annual Biotechnology Conference (New York, NY) – Markus Warmuth, M.D., Chief Executive Officer, to participate in fireside chat, February 7, 2024, at 1:30 p.m.
2023-11-21 07:00:00 - GlobeNewsWire
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in a fireside discussion at the 35th Annual Piper Sandler Healthcare Conference in New York City on Tuesday, November 28, 2023, at 3:30 p.m. ET. A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa's website at ir.monterosatx.com, and an archived version will be made available for 90 days following the presentation.
2023-10-27 07:00:00 - GlobeNewsWire
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: TD Cowen 7th Annual Fall Oncology Innovation Summit (virtual) – Fireside Chat, November 3, 2023, 1:00 p.m. ET Jefferies London Healthcare Conference (London, UK) – Investor meetings, November 14-15, 2023 The webcasted presentation will be accessible via the “Events & Presentations” section of Monte Rosa's website at ir.monterosatx.com, and an archived version will be made available for 90 days following the presentation.
2023-10-24 11:18:31 - Zacks Investment Research
Down -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics (GLUE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2023-05-30 16:30:00 - GlobeNewsWire
Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company is scheduled to present at the following investor and industry events in June:
2023-02-03 07:30:00 - GlobeNewsWire
Monte Rosa Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company is scheduled to participate in fireside chats and industry panels, as well as present at the following upcoming investor events: